We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.48%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.76B
AUM Growth
+$143M
Cap. Flow
-$59.1M
Cap. Flow %
-2.14%
Top 10 Hldgs %
30.84%
Holding
95
New
14
Increased
24
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$38.3M
2
HCA icon
HCA Healthcare
HCA
+$34.9M
3
BIIB icon
Biogen
BIIB
+$29.6M
4
PEN icon
Penumbra
PEN
+$28.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$80.8M
2
PFE icon
Pfizer
PFE
+$70.4M
3
MRK icon
Merck
MRK
+$54.6M
4
BDX icon
Becton Dickinson
BDX
+$32.2M
5
UHS icon
Universal Health Services
UHS
+$32M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
26
DELISTED
Verve Therapeutics
VERV
$40.1M 1.45%
1,168,808
+323,622
+38% +$10.3M
DVAX
27
DELISTED
Dynavax Technologies
DVAX
$39.7M 1.44%
3,805,370
– –
EW icon
28
Edwards Lifesciences
EW
$51.1B
$39.7M 1.44%
480,256
+142,101
+42% +$13.7M
PEN icon
29
CALL
Penumbra
PEN
$12.7B
$39.3M 1.42%
+207,500
New +$33.3M
CI icon
30
Cigna
CI
$74.5B
$39.2M 1.42%
141,300
– –
BIIB icon
31
Biogen
BIIB
$29.8B
$37.2M 1.35%
+139,326
New +$29.6M
ARGX icon
32
argenx
ARGX
$52B
$37M 1.34%
104,732
– –
MCK icon
33
McKesson
MCK
$96.8B
$36M 1.3%
105,811
– –
PNT
34
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$34.9M 1.26%
+4,515,216
New +$38.3M
VEEV icon
35
Veeva Systems
VEEV
$33.5B
$33.4M 1.21%
202,387
– –
HCA icon
36
HCA Healthcare
HCA
$88B
$32.2M 1.17%
+175,235
New +$34.9M
WAT icon
37
Waters Corp
WAT
$36.8B
$31.7M 1.15%
117,634
– –
AZN icon
38
AstraZeneca
AZN
$245B
$31.6M 1.14%
288,400
– –
TMO icon
39
Thermo Fisher Scientific
TMO
$213B
$31.5M 1.14%
62,143
– –
MRK icon
40
Merck
MRK
$316B
$31M 1.12%
360,520
-611,478
-63% -$54.6M
SNDX icon
41
Syndax Pharmaceuticals
SNDX
$1.7B
$31M 1.12%
1,289,073
+708,305
+122% +$15.9M
KRTX
42
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$29.3M 1.06%
130,293
– –
THC icon
43
Tenet Healthcare
THC
$20.1B
$28.1M 1.02%
544,583
– –
BCRX icon
44
BioCryst Pharmaceuticals
BCRX
$2.24B
$27.2M 0.99%
2,162,411
– –
NVRO
45
DELISTED
NEVRO CORP.
NVRO
$26.3M 0.95%
563,560
-95,850
-15% -$4.45M
ICLR icon
46
Icon
ICLR
$12.2B
$24.8M 0.9%
134,740
-23,443
-15% -$5.1M
ICUI icon
47
ICU Medical
ICUI
$4.32B
$24.1M 0.87%
160,250
-81,935
-34% -$13.6M
JNJ icon
48
Johnson & Johnson
JNJ
$613B
$22.5M 0.81%
137,746
-477,318
-78% -$80.8M
PRCT icon
49
Procept Biorobotics
PRCT
$1.05B
$21.5M 0.78%
517,526
+160,034
+45% +$6.38M
NTLA icon
50
Intellia Therapeutics
NTLA
$1.5B
$19.3M 0.7%
344,868
+181,588
+111% +$11.3M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q3 2022 Portfolio in Review

As of Q3 2022, PFM Health Sciences held 95 positions worth $2.76B, up 5.4% from $2.62B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

PFM Health Sciences's Q3 2022 filing shows 14 new, 24 increased, 13 reduced and 10 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M. The largest sale was Johnson & Johnson, an estimated $80.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Financials.

  • PFM Health Sciences's largest Q3 2022 buy was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M.
  • PFM Health Sciences added most to Penumbra in Q3 2022, an estimated $28.4M increase.
  • PFM Health Sciences's biggest Q3 2022 reduction was Johnson & Johnson, cutting an estimated $80.8M.
  • PFM Health Sciences fully exited Pfizer in Q3 2022, selling an estimated $70.4M.
  • PFM Health Sciences's ten largest holdings make up 31% of its $2.76B portfolio in Q3 2022.
  • PFM Health Sciences opened 14 new positions and closed 10 in Q3 2022.
  • PFM Health Sciences's portfolio value rose 5.4% quarter-over-quarter to $2.76B.

Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.